• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Skip to investors navigation
Insmed

Insmed

Powered by Purpose

LinkedIn Twitter Contact Us Job Opportunities

  • Culture
    • Our Culture
      • Mission & Vision
      • Careers
      • Responsibility
        • Inclusion at Insmed
        • Grants & Funding
        • Global Healthcare Compliance

    Our Global Company

    Find available career opportunities in the U.S., Japan, or Europe.

    Find Jobs

  • Patients
    • Our Patients
      • Disease Areas
      • Resources
      • Patient Access

    Current Clinical Trials

    You may be eligible for one of our clinical trials.

    See if you may qualify

  • Science
    • Our Science
      • ARIKAYCE®
      • Our Research
      • Pipeline
      • Clinical Trials
      • Investigator-Initiated Research

    Our Research Team

    Working together to develop new medicines and technologies that have the potential to transform patients’ lives.

    Learn More

  • About
    • About Insmed
    • Management Team
    • Board of Directors
    • Partnerships
  • Investors
    • Investors
    • Events & Presentations
    • Stock Information
    • News Releases
    • SEC Filings
    • Annual Reports
    • Analyst Coverage
    • Corporate Governance
    • Email Alerts
    • Investor FAQs
Home / Investors/ News Releases

News Releases

Month Year
Su Mo Tu We Th Fr Sa
Month Year
Su Mo Tu We Th Fr Sa
Email Alerts
Advanced Search
  
Asset Types
           
 Basic Search
  • Jul 8, 2013
    Insmed to Present at the 8th Annual JMP Securities Healthcare Conference
  • Jul 1, 2013
    ARIKACE Meets Primary Endpoint of Non-Inferiority to TOBI in Phase 3 Clinical Trial in Europe and Canada to Treat Pseudomonas aeruginosa in Cystic Fibrosis Patients
    ARIKACE Receives Qualified Infectious Disease Product and Fast Track Designations from the U.S. FDA for the Treatment of Non-Tuberculous Mycobacteria Lung Infections
  • Jun 28, 2013
    Insmed to Join the Russell Global(R) and Russell 3000(R) Indexes
  • Jun 28, 2013
    Insmed to Report Top-Line Results From Phase 3 Clinical Trial of ARIKACE to Treat Pseudomonas Aeruginosa in Cystic Fibrosis
  • May 14, 2013
    Insmed Granted Key Composition of Matter Patent Allowance for ARIKACE in Europe
  • May 13, 2013
    Insmed to Present at the UBS Global Healthcare Conference
  • May 10, 2013
    Insmed to Present at the Bank of America Merrill Lynch 2013 Health Care Conference
  • May 7, 2013
    Insmed Reports First Quarter Financial Results
  • May 1, 2013
    Insmed to Host First Quarter 2013 Financial Results Conference Call on Tuesday, May 7, 2013
  • Apr 18, 2013
    Insmed to Present at the 12th Annual Needham Healthcare Conference
  • Apr 1, 2013
    Insmed Appoints Matthew Pauls as Chief Commercial Officer
  • Mar 28, 2013
    ARIKACE Receives Orphan Drug Designation for Treating Infections Caused by Non-Tuberculous Mycobacteria
  • Mar 27, 2013
    Insmed to Present at Future Leaders in the Biotech Industry Conference
  • Mar 18, 2013
    Insmed Reports Fourth Quarter and Full Year 2012 Financial Results
  • Mar 11, 2013
    Insmed to Host Fourth Quarter and Full Year 2012 Financial Results Conference Call on Monday, March 18, 2013
  • Feb 26, 2013
    Insmed to Present at Two Upcoming Investor Conferences
  • Feb 6, 2013
    Insmed to Present at Two Upcoming Healthcare Investor Conferences
  • Dec 13, 2012
    Insmed to Present at 31st Annual J.P. Morgan Healthcare Conference
  • Nov 13, 2012
    Insmed Announces CLEAR-108 Phase 3 Clinical Study of ARIKACE® in Cystic Fibrosis Patients with Pseudomonas Lung Infections Has Completed Target Enrollment
  • Nov 12, 2012
    Insmed To Present At Two Upcoming Investor Conferences
  • Nov 7, 2012
    Insmed Appoints 15-Year Life Sciences Industry Veteran Andrew Drechsler as Chief Financial Officer
  • Nov 7, 2012
    Insmed Announces Financial Results for Third Quarter and Nine-Months Ended September 30, 2012
  • Oct 24, 2012
    Insmed to Host 2012 Third Quarter Earnings Conference Call
  • Sep 28, 2012
    Insmed Announces Pricing of Approximately $26 Million Direct Public Offering
  • Aug 30, 2012
    Insmed to Present at Stifel Nicolaus 2012 Healthcare Conference
  • Aug 14, 2012
    Insmed to Present at 2012 Wedbush PacGrow Life Sciences Management Access Conference
  • Aug 7, 2012
    Insmed Announces Financial Results For Second Quarter And Six-months Ended June 30, 2012
  • Aug 6, 2012
    Pharmaceutical Industry Veteran Al Altomari Elected To Insmed's Board Of Directors
  • Aug 2, 2012
    Insmed Receives Second Composition Of Matter Patent For ARIKACE®
  • Jul 30, 2012
    Insmed Announces Planned Departure Of Chief Financial Officer
  • Jul 24, 2012
    Insmed to Host 2012 Second Quarter Earnings Conference Call
  • Jul 10, 2012
    Insmed To Present At JMP Securities 7th Annual Healthcare Conference
  • Jul 2, 2012
    Insmed Secures $20 Million Loan Agreement With Hercules Technology Growth Capital
  • Jun 27, 2012
    Insmed Announces First Patient Dosed in TARGET-NTM Phase 2 Clinical Trial of ARIKACE® in Patients with Non-Tuberculous Mycobacteria (NTM) Lung Disease
  • May 30, 2012
    Insmed Provides Corporate Update
  • May 23, 2012
    Insmed Incorporated Begins Screening Patients For TARGET-NTM U.S. Clinical Trial Of ARIKACE® In Patients With Non-tuberculous Mycobacterial Lung Disease
  • May 16, 2012
    Insmed Appoints Donald J. Hayden, Jr. as Executive Chairman
  • May 8, 2012
    Insmed Announces First Quarter 2012 Financial Results
  • May 7, 2012
    Insmed Incorporated Announces Lifting of Clinical Hold by U.S. Food and Drug Administration on ARIKACE® in Cystic Fibrosis Patients With Pseudomonas Lung Infections
  • Apr 24, 2012
    Insmed to Host 2012 First Quarter Earnings Conference Call
  • Apr 16, 2012
    Insmed Announces First Patient Dosed in Pivotal European Phase 3 Clinical Study of ARIKACE® in Cystic Fibrosis Patients with Pseudomonas Lung Infections
  • Mar 13, 2012
    Insmed Announces Fourth Quarter and Full-Year 2011 Financial Results
  • Feb 28, 2012
    Insmed to Host Fourth Quarter and 2011 Year-End Earnings Conference Call
  • Feb 10, 2012
    Insmed Incorporated Provides Update on Clinical Program for ARIKACE®
  • Jan 20, 2012
    Insmed Incorporated Provides Corporate Update
  • Nov 14, 2011
    Insmed to Present at Lazard Capital Markets 8th Annual Healthcare Conference
  • Nov 8, 2011
    Insmed Announces Financial Results for Third Quarter and Nine-Months Ended September 30, 2011
  • Oct 25, 2011
    Insmed to Host 2011 Third Quarter Earnings Conference Call
  • Oct 24, 2011
    Insmed Incorporated Provides Regulatory Update on ARIKACE® in Non-Tuberculous Mycobacteria Indication
  • Oct 10, 2011
    Insmed Incorporated Provides Regulatory Update
Show 5102550100 per page
  • «
  • 1
  • …
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • …
  • 13
  • »
Stay In The Loop

Want to stay up to date on our news, events, and filings? Set up your
email alerts.

Sign Up

View the latest Insmed Investor Presentation

Download

Primary Sidebar

Investor Menu

  • Investors
  • Events & Presentations
  • Stock Information
  • News Releases
  • SEC Filings
  • Annual Reports
  • Analyst Coverage
  • Corporate Governance
  • Email Alerts
  • Investor FAQs

Investor Menu

Footer

Insmed
LinkedIn Twitter

Contact Us

Job Opportunities

  • Our Culture
    • Mission & Vision
    • Careers
    • Responsibility
      • Inclusion at Insmed
      • Grants & Funding
      • Global Healthcare Compliance
  • Our Patients
    • Disease Areas
    • Resources
    • Patient Access
  • Our Science
    • ARIKAYCE®
    • Our Research
    • Pipeline
    • Clinical Trials
    • Investigator-Initiated Research
  • About
    • Management Team
    • Board of Directors
    • Partnerships
  • Investors
  • Events & Presentations
  • Stock Information
  • News Releases
  • SEC Filings
  • Annual Reports
  • Analyst Coverage
  • Corporate Governance
  • Email Alerts
  • Investor FAQs

© 2023 Insmed Incorporated. All Rights Reserved. Terms of Use Privacy Policy

Culture
Patients
Science
logo
  • Culture
    • Mission & Vision
    • Careers
    • Responsibility
      • Inclusion at Insmed
      • Grants & Funding
      • Global Healthcare Compliance
  • Patients
    • Disease Areas
    • Resources
    • Patient Access
  • Science
    • ARIKAYCE®
    • Our Research
    • Pipeline
    • Clinical Trials
    • Investigator-Initiated Research
  • About
    • Management Team
    • Board of Directors
    • Partnerships
  • Investors
    • Investors
    • Events & Presentations
    • Stock Information
    • News Releases
    • SEC Filings
    • Annual Reports
    • Analyst Coverage
    • Corporate Governance
    • Email Alerts
    • Investor FAQs

LinkedIn Twitter

Contact Us Job Opportunities

© 2023 Insmed Incorporated.
All Rights Reserved.

Terms of Use Privacy Policy